[{"id":"ca7e4b34-6f76-4ea3-8c6b-e39973324752","acronym":"NRG-LU003","url":"https://clinicaltrials.gov/study/NCT03737994","created_at":"2023-11-21T21:15:46.432Z","updated_at":"2025-02-25T12:37:11.248Z","phase":"Phase 2","brief_title":"Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer","source_id_and_acronym":"NCT03737994 - NRG-LU003","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MET","pipe":" | ","alterations":" ALK positive • MET amplification • ALK rearrangement","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • MET amplification • ALK rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Xalkori (crizotinib) • carboplatin • Alecensa (alectinib) • Lorbrena (lorlatinib) • Zykadia (ceritinib) • pemetrexed • Alunbrig (brigatinib) • Ensacove (ensartinib) • Pemfexy (pemetrexed)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 07/25/2019","start_date":" 07/25/2019","primary_txt":" Primary completion: 07/21/2021","primary_completion_date":" 07/21/2021","study_txt":" Completion: 12/02/2025","study_completion_date":" 12/02/2025","last_update_posted":"2025-02-24"},{"id":"6da256ca-a5e6-48f5-9386-baa4180b20fa","acronym":"","url":"https://clinicaltrials.gov/study/NCT03420508","created_at":"2021-01-18T16:52:29.427Z","updated_at":"2025-02-25T16:52:07.457Z","phase":"Phase 2","brief_title":"Treating Patients With Melanoma and ALK Alterations With Ensartinib","source_id_and_acronym":"NCT03420508","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" BRAF • ALK","pipe":" | ","alterations":" BRAF V600 • ALK fusion • ALK mutation","tags":["BRAF • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600 • ALK fusion • ALK mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ensacove (ensartinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 01/10/2018","start_date":" 01/10/2018","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 01/01/2026","study_completion_date":" 01/01/2026","last_update_posted":"2025-02-04"},{"id":"e098103f-75c1-4aa9-b386-41c1d51fb602","acronym":"MATCH","url":"https://clinicaltrials.gov/study/NCT03155620","created_at":"2021-01-18T15:33:32.929Z","updated_at":"2025-02-25T16:51:52.930Z","phase":"Phase 2","brief_title":"Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)","source_id_and_acronym":"NCT03155620 - MATCH","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Ibrance (palbociclib) • Zelboraf (vemurafenib) • Vitrakvi (larotrectinib) • Koselugo (selumetinib) • Balversa (erdafitinib) • Retevmo (selpercatinib) • Ensacove (ensartinib) • Zarnestra (tipifarnib) • Tazverik (tazemetostat) • ulixertinib (BVD-523) • samotolisib (LY3023414)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 2316","initiation":"Initiation: 07/31/2017","start_date":" 07/31/2017","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2025-02-04"},{"id":"5fd0fa10-b9be-455c-a7e5-659b29c2c4c3","acronym":"eXalt3","url":"https://clinicaltrials.gov/study/NCT02767804","created_at":"2021-01-18T13:34:22.303Z","updated_at":"2024-07-02T16:35:04.691Z","phase":"Phase 3","brief_title":"eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients","source_id_and_acronym":"NCT02767804 - eXalt3","lead_sponsor":"Xcovery Holdings, Inc.","biomarkers":" ALK","pipe":" | ","alterations":" ALK positive","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xalkori (crizotinib) • Ensacove (ensartinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 290","initiation":"Initiation: 06/01/2016","start_date":" 06/01/2016","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-05-09"},{"id":"5d0a56a5-b571-42b6-8616-808c0183587b","acronym":"EAGLE","url":"https://clinicaltrials.gov/study/NCT05491811","created_at":"2022-08-08T11:56:38.924Z","updated_at":"2024-07-02T16:35:06.336Z","phase":"Phase 2","brief_title":"Ensartinib in Combination With Bevacizumab in ALK-positive NSCLC Patients With TP53 Mutation","source_id_and_acronym":"NCT05491811 - EAGLE","lead_sponsor":"Sun Yat-sen University","biomarkers":" ALK • TP53","pipe":" | ","alterations":" TP53 mutation • ALK positive • ALK mutation","tags":["ALK • TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • ALK positive • ALK mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Ensacove (ensartinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 58","initiation":"Initiation: 08/01/2022","start_date":" 08/01/2022","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-05-02"},{"id":"2c95990f-5d17-4530-96c0-0a4a38d9ef68","acronym":"","url":"https://clinicaltrials.gov/study/NCT05241028","created_at":"2022-02-15T15:52:42.960Z","updated_at":"2024-07-02T16:35:34.021Z","phase":"Phase 2","brief_title":"Adjuvant Therapy of Ensartinib in Stage IB-IIIA ALK-positive Non-small Cell Lung Cancer","source_id_and_acronym":"NCT05241028","lead_sponsor":"Hebei Medical University Fourth Hospital","biomarkers":" ALK","pipe":" | ","alterations":" ALK positive • ALK fusion","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • ALK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ensacove (ensartinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 05/01/2022","start_date":" 05/01/2022","primary_txt":" Primary completion: 02/01/2027","primary_completion_date":" 02/01/2027","study_txt":" Completion: 02/01/2029","study_completion_date":" 02/01/2029","last_update_posted":"2023-10-10"},{"id":"bce35de4-31d1-4a8c-be0e-72c3b731e4e4","acronym":"","url":"https://clinicaltrials.gov/study/NCT02959619","created_at":"2021-01-17T17:17:11.764Z","updated_at":"2024-07-02T16:35:39.439Z","phase":"Phase 1","brief_title":"Ensartinib in Non-small Cell Lung Cancer Patients With Positive ALK","source_id_and_acronym":"NCT02959619","lead_sponsor":"Betta Pharmaceuticals Co., Ltd.","biomarkers":" ALK","pipe":"","alterations":" ","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ensacove (ensartinib)"],"overall_status":"Completed","enrollment":" Enrollment 48","initiation":"Initiation: 03/06/2017","start_date":" 03/06/2017","primary_txt":" Primary completion: 10/31/2019","primary_completion_date":" 10/31/2019","study_txt":" Completion: 04/23/2020","study_completion_date":" 04/23/2020","last_update_posted":"2023-08-21"},{"id":"283a5e85-a6d2-41d2-bd82-3b4b8b03e157","acronym":"","url":"https://clinicaltrials.gov/study/NCT03215693","created_at":"2021-01-17T17:25:13.004Z","updated_at":"2024-07-02T16:35:39.915Z","phase":"Phase 2","brief_title":"X-396 Capsule in Patients With ALK-positive Non-small Cell Lung Cancer Previously Treated With Crizotinib","source_id_and_acronym":"NCT03215693","lead_sponsor":"Betta Pharmaceuticals Co., Ltd.","biomarkers":" ALK","pipe":" | ","alterations":" ALK positive","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xalkori (crizotinib) • Ensacove (ensartinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 152","initiation":"Initiation: 09/28/2017","start_date":" 09/28/2017","primary_txt":" Primary completion: 03/09/2020","primary_completion_date":" 03/09/2020","study_txt":" Completion: 12/01/2023","study_completion_date":" 12/01/2023","last_update_posted":"2023-08-16"},{"id":"5677adc4-a896-4714-924b-c8f5d4257f3e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05341583","created_at":"2022-04-22T13:53:36.513Z","updated_at":"2024-07-02T16:35:42.942Z","phase":"Phase 3","brief_title":"Ensartinib as Adjuvant Treatment in Anaplastic Lymphoma Kinase (ALK) Positive Non-small Cell Lung Cancer","source_id_and_acronym":"NCT05341583","lead_sponsor":"Betta Pharmaceuticals Co., Ltd.","biomarkers":" ALK","pipe":" | ","alterations":" ALK positive","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ensacove (ensartinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 202","initiation":"Initiation: 05/24/2022","start_date":" 05/24/2022","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 07/23/2025","study_completion_date":" 07/23/2025","last_update_posted":"2023-07-14"},{"id":"4ceb856c-ebc1-4e21-af26-f19a10370598","acronym":"","url":"https://clinicaltrials.gov/study/NCT04146571","created_at":"2021-01-18T20:14:15.797Z","updated_at":"2024-07-02T16:36:02.095Z","phase":"","brief_title":"Expanded Access to Ensartinib for Participants With ALK+ NSCLC","source_id_and_acronym":"NCT04146571","lead_sponsor":"Xcovery Holding Company, LLC","biomarkers":" ALK","pipe":" | ","alterations":" ALK positive","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ensacove (ensartinib)"],"overall_status":"Available","enrollment":"","initiation":"","start_date":"","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2022-10-20"},{"id":"01e61b9a-3c5b-46fa-bd98-bd47903e06a1","acronym":"","url":"https://clinicaltrials.gov/study/NCT05380024","created_at":"2022-05-18T11:57:03.319Z","updated_at":"2024-07-02T16:36:05.202Z","phase":"Phase 2","brief_title":"A Study of Ensartinib as Neoadjuvant Therapy for Patients With ALK Positive Resectable Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT05380024","lead_sponsor":"Peking University Cancer Hospital \u0026 Institute","biomarkers":" ALK","pipe":" | ","alterations":" ALK positive","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ensacove (ensartinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 08/17/2022","start_date":" 08/17/2022","primary_txt":" Primary completion: 12/30/2023","primary_completion_date":" 12/30/2023","study_txt":" Completion: 06/30/2024","study_completion_date":" 06/30/2024","last_update_posted":"2022-08-18"},{"id":"03ba1cfe-a5a1-4e3c-b99e-3b35e2c48034","acronym":"","url":"https://clinicaltrials.gov/study/NCT05498064","created_at":"2022-11-08T19:21:11.258Z","updated_at":"2024-07-02T16:36:05.624Z","phase":"","brief_title":"A Real World Study of Ensartinib in Advanced ALK-positive NSCLC","source_id_and_acronym":"NCT05498064","lead_sponsor":"Peking Union Medical College Hospital","biomarkers":" ALK","pipe":" | ","alterations":" ALK positive","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ensacove (ensartinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 490","initiation":"Initiation: 05/13/2022","start_date":" 05/13/2022","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/01/2028","study_completion_date":" 12/01/2028","last_update_posted":"2022-08-11"},{"id":"ca3962da-19ce-4c5d-a428-6684259baaca","acronym":"","url":"https://clinicaltrials.gov/study/NCT05186506","created_at":"2022-01-11T15:56:03.618Z","updated_at":"2024-07-02T16:36:18.698Z","phase":"Phase 2","brief_title":"A Study Comparing Ensatinib Versus Platinum-Based Chemotherapy as Adjuvant Treatment for Stage II-IIIA ALK -Positive Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT05186506","lead_sponsor":"Sichuan University","biomarkers":" ALK","pipe":" | ","alterations":" ALK positive","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • paclitaxel • Ensacove (ensartinib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 152","initiation":"Initiation: 01/01/2022","start_date":" 01/01/2022","primary_txt":" Primary completion: 12/15/2025","primary_completion_date":" 12/15/2025","study_txt":" Completion: 12/20/2028","study_completion_date":" 12/20/2028","last_update_posted":"2022-01-11"},{"id":"4c274bdb-45a9-44a6-a28a-d6de2c125b86","acronym":"ERSGATR","url":"https://clinicaltrials.gov/study/NCT05178511","created_at":"2022-01-05T12:53:39.447Z","updated_at":"2024-07-02T16:36:18.830Z","phase":"Phase 2","brief_title":"Ensatinib Treat Second-generation ALK-TKI Resistance After Second-generation ALK-TKI Resistance","source_id_and_acronym":"NCT05178511 - ERSGATR","lead_sponsor":"Li Zhang, MD","biomarkers":" ALK","pipe":" | ","alterations":" ALK positive","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ensacove (ensartinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 12/01/2021","start_date":" 12/01/2021","primary_txt":" Primary completion: 07/01/2023","primary_completion_date":" 07/01/2023","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2022-01-05"},{"id":"7b56814f-abfa-48af-ac04-b6c7cef7e152","acronym":"","url":"https://clinicaltrials.gov/study/NCT01625234","created_at":"2021-01-18T06:58:28.125Z","updated_at":"2024-07-02T16:36:23.426Z","phase":"Phase 1/2","brief_title":"Phase 1/2 Study of X-396, an Oral ALK Inhibitor, in Patients With ALK-positive Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT01625234","lead_sponsor":"Xcovery Holding Company, LLC","biomarkers":" ALK","pipe":" | ","alterations":" ALK mutation","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ensacove (ensartinib)"],"overall_status":"Completed","enrollment":" Enrollment 131","initiation":"Initiation: 06/01/2012","start_date":" 06/01/2012","primary_txt":" Primary completion: 09/17/2020","primary_completion_date":" 09/17/2020","study_txt":" Completion: 09/17/2020","study_completion_date":" 09/17/2020","last_update_posted":"2021-10-06"},{"id":"24b69423-b667-4fec-bd84-dccd39a78fbc","acronym":"","url":"https://clinicaltrials.gov/study/NCT04415320","created_at":"2021-01-18T21:16:55.072Z","updated_at":"2024-07-02T16:36:44.509Z","phase":"Phase 2","brief_title":"X-396 (Ensartinib) Capsules in ALK-Positive NSCLC Patients With Brain Metastases","source_id_and_acronym":"NCT04415320","lead_sponsor":"Betta Pharmaceuticals Co., Ltd.","biomarkers":" ALK","pipe":" | ","alterations":" ALK positive • ALK mutation","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • ALK mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ensacove (ensartinib)"],"overall_status":"Unknown status","enrollment":" Enrollment 37","initiation":"Initiation: 03/21/2019","start_date":" 03/21/2019","primary_txt":" Primary completion: 12/01/2020","primary_completion_date":" 12/01/2020","study_txt":" Completion: 06/01/2021","study_completion_date":" 06/01/2021","last_update_posted":"2020-06-04"},{"id":"1d6df4dc-ab5a-476b-b084-ff6b7182621b","acronym":"","url":"https://clinicaltrials.gov/study/NCT03608007","created_at":"2021-01-18T17:44:12.629Z","updated_at":"2024-07-02T16:36:51.515Z","phase":"Phase 2","brief_title":"X-396 Capsule in Advanced NSCLC Patients With ROS1 Gene Rearrangement","source_id_and_acronym":"NCT03608007","lead_sponsor":"Betta Pharmaceuticals Co., Ltd.","biomarkers":" ROS1","pipe":"","alterations":" ","tags":["ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ensacove (ensartinib)"],"overall_status":"Unknown status","enrollment":" Enrollment 69","initiation":"Initiation: 06/15/2018","start_date":" 06/15/2018","primary_txt":" Primary completion: 03/01/2020","primary_completion_date":" 03/01/2020","study_txt":" Completion: 09/01/2020","study_completion_date":" 09/01/2020","last_update_posted":"2020-01-09"},{"id":"9ba5e842-b8f1-4c98-93b9-54a9cd5e5e45","acronym":"","url":"https://clinicaltrials.gov/study/NCT03753685","created_at":"2021-01-18T18:27:17.114Z","updated_at":"2024-07-02T16:37:05.067Z","phase":"Phase 2","brief_title":"X-396(Ensartinib) Capsules in ALK-Positive NSCLC Patients With Brain Metastases","source_id_and_acronym":"NCT03753685","lead_sponsor":"Fudan University","biomarkers":" ALK","pipe":" | ","alterations":" ALK positive • ALK mutation","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • ALK mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ensacove (ensartinib)"],"overall_status":"Unknown status","enrollment":" Enrollment 37","initiation":"Initiation: 12/01/2018","start_date":" 12/01/2018","primary_txt":" Primary completion: 07/01/2020","primary_completion_date":" 07/01/2020","study_txt":" Completion: 10/01/2020","study_completion_date":" 10/01/2020","last_update_posted":"2018-11-27"}]